Company intelligence / Profile preview

Betemar

Hangzhou, Zhejiang, Chinabetemar.com.tr ↗

Ownership: Private
Employees: ~1700
Development stage: Other

Overview

Betta Pharmaceuticals has developed and commercialized several innovative oncology drugs, including icotinib hydrochloride (Conmana®), befotertinib (Surmana®), and vorolanib. Their pipeline includes over twenty programs at various clinical stages. Notably, ensartinib has been submitted for FDA review as a potential first-in-class global launch from a Chinese company. Clinical results include approvals by China's NMPA and positive recognition by international journals such as The Lancet Respiratory Medicine.

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyBiologic
Industry: Biotech

Drug pipeline

1 asset

Betemar-CD3-TT3

Preclinical

Partnerships

Not specified; likely includes academic collaborations via the Dreamworks incubator platform.

Beyond the preview

Go deeper on Betemar.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Betemar.

Explore the full profile